Quick Answer
Cellectar Biosciences, Inc. reported Diluted EPS of $8.35 per share (loss) for fiscal year 2025.
Cellectar Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.35 | +80.1% |
| 2024 | -$41.89 | -1096.9% |
| 2023 | -$3.50 | +13.6% |
| 2022 | -$4.05 | +6.9% |
| 2021 | -$4.35 | -136.4% |
| 2020 | -$1.84 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.41 | +88.4% | +58.4% |
| June 30, 2025 | -$3.39 | +37.6% | -2321.4% |
| March 31, 2025 | -$0.14 | +84.6% | +98.8% |
| September 30, 2024 | -$12.13 | -682.6% | -123.4% |
| June 30, 2024 | -$5.43 | -503.3% | -496.7% |
| March 31, 2024 | -$0.91 | -19.7% | +41.3% |
| September 30, 2023 | -$1.55 | -21.1% | -72.2% |
| June 30, 2023 | -$0.90 | +26.2% | -18.4% |
- Cellectar Biosciences, Inc. showed an increase of +80.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Cellectar Biosciences, Inc.’s diluted eps has declined by 353.8% (from $1.84 per share (loss) to $8.35 per share (loss)).
- The most recent figure is from Cellectar Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: